Table 3. Main clinical and laboratory parameters in eight patients with IMN from rituximab administration (month 0) to study end (month 12)

ParameterMonths
01236912
a P < 0.01 and
b P ≤ 0.05 versus month 0.
Systolic BP (mmHg)131 ± 11125 ± 10129 ± 11129 ± 11131 ± 9131 ± 14128 ± 4
Diastolic BP (mmHg)83 ± 778 ± 1081 ± 680 ± 678 ± 978 ± 774 ± 11
Body weight (kg)78 ± 1676 ± 1575 ± 15b75 ± 15b74 ± 14b75 ± 1575 ± 15
Scr (mg/dl)1.5 ± 0.91.5 ± 0.81.4 ± 0.71.4 ± 0.81.4 ± 0.81.3 ± 0.71.4 ± 0.7
CrCl (ml/min per 1.73 m2)69 ± 3168 ± 3068 ± 3071 ± 2675 ± 3276 ± 2871 ± 26
Urinary protein excretion (g/24 h)8.6 ± 4.23.7 ± 2.4a4.1 ± 2.5a4.3 ± 3.3a4.1 ± 3.1a3.6 ± 2.7a3.0 ± 2.5a
Albumin fractional clearance2.3 ± 2.11.3 ± 1.4a1.3 ± 1.9b1.2 ± 1.7b1.0 ± 1.0a0.8 ± 0.7a0.5 ± 0.6a
Serum albumin (mg/dl)2.7 ± 0.53.0 ± 0.4a3.1 ± 0.3b3.1 ± 0.3b3.3 ± 0.3a3.4 ± 0.3b3.5 ± 0.4b
Serum cholesterol (mg/dl)236 ± 75239 ± 82221 ± 60238 ± 48210 ± 57208 ± 59184 ± 45b
Serum triglycerides (mg/dl)186 ± 183195 ± 121204 ± 139221 ± 138206 ± 132195 ± 121165 ± 115